Potential for Maternally Administered Vaccine for Infant Group B Streptococcus
Background: Natural history studies have correlated serotype-specific anti-capsular polysaccharide (CPS) IgG in newborns with a reduced risk of group B streptococcal disease. A hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine (GBS6) is being developed as a maternal vaccine to prevent invasive group B streptococcus in young infants.
45
2023-08-22(万方平台首次上网日期,不代表论文的发表时间)
共1页
1384